This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Auxilium Announces Appointments To Enhance Leadership Team

MALVERN, Pa., Feb. 6, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced the appointment of two executive officers, effective immediately.  Andrew I. Koven has been named Executive Vice President, Chief Administrative Officer and General Counsel, and Mark A. Glickman has been named Senior Vice President, Sales.

"The leadership appointments we are announcing today advance our efforts to help position Auxilium for sustainable success and the next stage of its evolution," said Adrian Adams, Chief Executive Officer and President of Auxilium.  "Collectively, Andrew and Mark's broad expertise and industry experience should significantly enhance our capabilities as we seek to maximize the value of XIAFLEX® and Testim®, deliver on our current pipeline, and capitalize on future growth opportunities to achieve profitability and drive shareholder value."

Mr. Koven has over 26 years of experience practicing law, most of which has been in the pharmaceutical industry.  He most recently served as President and Chief Administrative Officer of Neurologix, Inc.  Prior to that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations prior to the strategic acquisition of the company by Merck & Co.  From 2007 to 2010 Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc. before its acquisition by Dainippon Sumitomo Pharma Co in 2009.  Before joining Sepracor, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., where he oversaw the company's legal, compliance and quality assurance departments until the acquisition of the company by Abbott Laboratories in 2006.  Mr. Koven began his career in the pharmaceutical industry as an Assistant General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003.  From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York.  In his new role, Mr. Koven will be assuming responsibility for the Company's legal functions, government affairs and technical operations.    

Mr. Glickman has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions and organizational expansions.  Most recently he was Vice President of the medical device division of Otsuka America Pharmaceutical, Inc., a U.S. division of the Tokyo-based Otsuka Pharmaceutical Company.  At Otsuka, he helped to reinvigorate the company's sales and increase its business by 50% over two years, while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings.  Prior to that, he served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., from 2007 to 2009, during which time he completed a successful turnaround of the company's commercial strategy, driving a significant increase in sales during his tenure.  Before joining Oscient, Mr. Glickman served as Vice President of Sales at Bayer Healthcare's Diabetes Care Division.  From 2001 to 2007 he played a major role in helping to build the commercial organization at Kos Pharmaceuticals by holding various positions including Director of Marketing, Regional Sales Director and Vice President of Sales.  Prior to that, he was a Senior Product Manager at Bristol-Myers Squibb, where, during his tenure, he contributed to revenue growth of $400 million.  

The Company also announced the departures of Jennifer Evans Stacey, Esq., the Company's Executive Vice President, General Counsel, and Secretary; Ed Kessig, Senior Vice President, Sales; and Edward Arcuri, Executive Vice President, Technical Operations.

"On behalf of the Auxilium Board of Directors and senior management team, I would like to thank Jennifer, Ed, and Edward for their contributions to the Company over the years," continued Mr. Adams. "Each has played an important role in Auxilium's successes and we wish them well in their future endeavors."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.20 1.70%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
YHOO $36.02 -1.40%
TSLA $232.12 -4.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,064.06 -17.37 -0.83%
NASDAQ 4,765.7860 -51.8080 -1.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs